Article thumbnail

PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach

By Xiaofeng Liu, Sisheng Ouyang, Biao Yu, Yabo Liu, Kai Huang, Jiayu Gong, Siyuan Zheng, Zhihua Li, Honglin Li and Hualiang Jiang

Abstract

In silico drug target identification, which includes many distinct algorithms for finding disease genes and proteins, is the first step in the drug discovery pipeline. When the 3D structures of the targets are available, the problem of target identification is usually converted to finding the best interaction mode between the potential target candidates and small molecule probes. Pharmacophore, which is the spatial arrangement of features essential for a molecule to interact with a specific target receptor, is an alternative method for achieving this goal apart from molecular docking method. PharmMapper server is a freely accessed web server designed to identify potential target candidates for the given small molecules (drugs, natural products or other newly discovered compounds with unidentified binding targets) using pharmacophore mapping approach. PharmMapper hosts a large, in-house repertoire of pharmacophore database (namely PharmTargetDB) annotated from all the targets information in TargetBank, BindingDB, DrugBank and potential drug target database, including over 7000 receptor-based pharmacophore models (covering over 1500 drug targets information). PharmMapper automatically finds the best mapping poses of the query molecule against all the pharmacophore models in PharmTargetDB and lists the top N best-fitted hits with appropriate target annotations, as well as respective molecule’s aligned poses are presented. Benefited from the highly efficient and robust triangle hashing mapping method, PharmMapper bears high throughput ability and only costs 1 h averagely to screen the whole PharmTargetDB. The protocol was successful in finding the proper targets among the top 300 pharmacophore candidates in the retrospective benchmarking test of tamoxifen. PharmMapper is available at http://59.78.96.61/pharmmapper

Topics: Articles
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2896160
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1983). Antagonistic action of estrogens, flutamide, and human growth hormone on androgen-induced changes in the activities of some enzymes of hepatic steroid metabolism in the rat.
  2. (2007). BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities.
  3. (2007). Chemogenomic approaches to rational drug design.
  4. (2007). Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint.
  5. (2008). Chemogenomics and biotechnology.
  6. (2006). Chemogenomics: drug discovery’s panacea?
  7. (1995). Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues.
  8. (2008). Computational analysis of ligand relationships within target families.
  9. (2004). Computational chemogenomics approaches to systematic knowledge-based drug discovery.
  10. (2009). Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.
  11. (2008). Drug target identification using side-effect similarity.
  12. (2008). DrugBank: a knowledgebase for drugs, drug actions and drug targets.
  13. (1985). Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line.
  14. (2004). Exploring the chemogenomic knowledge space with annotated chemical libraries.
  15. (2005). Finding new tricks for old drugs: an efficient route for public-sector drug discovery.
  16. (1993). From atoms and bonds to 3-dimensional atomic coordinates - automatic model builders.
  17. High throughput structure-based pharmacophore modeling as a basis for successful parallel virtual screening.
  18. (2006). How many drug targets are there?
  19. (1993). Inhibition of estrone sulfatase and 17beta-hydroxysteroid dehydrogenase by antiestrogens.
  20. (1990). Leu-enkephalin, tamoxifen and ethanol interactions: effects on motility and hepatic ethanol metabolizing enzymes.
  21. (2005). LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters.
  22. (2007). MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells.
  23. (2004). Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.
  24. (1997). PDBsum: a Web-based database of summaries and analyses of all PDB structures.
  25. (2008). PDTD: a web-accessible protein database for drug target identification.
  26. (1996). Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen.
  27. (2004). Proteomics reveals that proteins expressed during the early stage of Bacillus anthracis infection are potential targets for the development of vaccines and drugs.
  28. (2008). Quantifying the relationships among drug classes.
  29. (2007). Relating protein pharmacology by ligand chemistry.
  30. (1989). Searching for pharmacophores in large coordinate data bases and its use in drug design.
  31. (1998). Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal.
  32. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil.
  33. (2009). Tamoxifen: the drug that came in from the cold.
  34. (2006). TarFisDock: a web server for identifying drug targets with docking approach.
  35. (1980). The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by tamoxifen.
  36. (2002). The druggable genome.
  37. (1991). The effect of toremifene therapy on serum immunoglobulin levels in breast cancer.
  38. (2004). The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures.
  39. (2000). The protein data bank.
  40. (2007). The universal protein resource (UniProt).
  41. (2006). Virtual ligand screening: strategies, perspectives and limitations.